Browse News
Filter News
Found 47 articles
-
Lunsumio™, Jaypirca™ Available at AllianceRx Walgreens Pharmacy for Treatment of Two Forms of Non-Hodgkin Lymphoma
5/17/2023
AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the U.S., will now distribute two medications indicated for adults with certain types of lymphoma.
-
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
4/19/2023
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab).
-
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
2/28/2023
ADC Therapeutics SA today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.
-
City of Hope-led trial leads to U.S. Food and Drug Administration's approval of a first of its kind bispecific antibody
1/5/2023
A trial led by City of Hope, one of the largest cancer research and treatment organizations in the nation, contributed to the U.S. Food and Drug Administration's approval of mosunetuzumab, the first bispecific antibody to treat people with relapsed or difficult to treat follicular lymphoma, a type of non-Hodgkin lymphoma, after they have received two or more standard therapies.
-
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
12/23/2022
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Lunsumio® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
-
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
12/19/2022
Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab.
-
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
12/12/2022
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, December 10-13, 2022.
-
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
12/11/2022
Genentech, a member of the Roche Group, announced that new and updated data for its first-in-class anti-CD79b antibody-drug conjugate Polivy® were presented at the 64th American Society of Hematology Annual Meeting & Exposition, December 10-13.
-
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Novel and Expansive Hematology/Oncology Data at the 64th American Society of Hematology Annual Meeting and Exposition
11/15/2022
Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present a wide-ranging scope of new hematology/oncology data from their clinical research program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, Louisiana (and virtually) from December 10-13, 2022.
-
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
11/3/2022
Genentech, a member of the Roche Group, announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022.
-
Bispecific Antibody Market USD 30 Billion Opportunity 600 Antibodies In Clinical Trials
8/18/2022
Several advances in the field of biotechnology, particularly antibody engineering has led to designing of next generation therapeutics with more enhanced efficacy and safety.
-
At Biogen's quarterly conference call, outgoing CEO Michel Vounatsos emphasized a strong balance sheet and 10 exciting late-stage programs. The company also raised its 2022 guidance.
-
Eisai and Biogen's BLA for lecanemab for Alzheimer's disease received FDA Priority Review with a target action date of January 6, 2023, while Roche's lymphoma drug scored the same designation.
-
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
7/6/2022
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
-
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
6/10/2022
Genentech, a member of the Roche Group, announced that it is presenting new long-term follow-up results and subanalyses from clinical trials of its approved therapies, as well as data on investigational medicines from its broad blood cancer portfolio, at the European Hematology Association 2022 Congress in Vienna.
-
Mosunetuzumab Conditional Approval Further Validates Bispecific Antibodies Development
5/27/2022
Mosunetuzumab Approval In USA & Other Markets In Next 2-3 Years To Drive Bispecific Antibodies Cumulative Sales To USD 60 Billion By 2028 Says Kuick Research.
-
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
5/26/2022
Genentech, a member of the Roche Group, announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7 and the European Hematology Association 2022 Congress from June 9-12.
-
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
5/24/2022
Genentech, a member of the Roche Group, announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2022.
-
Hemlibra Sales Driving Global Bispecific Antibodies Market
5/11/2022
Hemlibra is bispecific antibody which restores the hemostatic process and indicated for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patient’s ages newborn and older with hemophilia A with or without factor VIII inhibitors.
-
Swiss pharma giant Roche predicts a revenue slowdown related to its COVID-19 products and the increasing challenge of biosimilar drugs.